Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women With Gestational Diabetes Mellitus
NCT ID: NCT04579016
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2020-01-13
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pregnancy Complications in Women With BMI>25 kg/m2 Enrolled in a Healthy Lifestyle and Eating Habits Program
NCT01783210
Intervention, Dietary, Diabetes, Pregnancy
NCT04690907
A Trial of Two Diets for Weight and Diabetes Management
NCT00729196
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
NCT05165706
Low Glycemic Index (GI) Diet Management for Pregnant Woman With Overweight
NCT01628835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is evidence that lifestyle changes (diet and physical activity), can reduce the development of type 2 diabetes in people at high risk, such as women with previous GDM. The postnatal period (shortly after pregnancy) is an ideal time for women to make these changes to help prevent weight gain between pregnancies and generally reduce their risk of future type 2 diabetes. This study is designed to determine if a postnatal lifestyle intervention will lead to weight reduction over a 12 month period post-delivery.
Women who have been diagnosed with diabetes during pregnancy (GDM) and had a body mass index (BMI) \>25 kg/m2 at the start of pregnancy, will be invited to take part in the study.
During their routine appointment at 32-36 weeks gestation women will be randomly allocated either to the intervention program or control group.
Women in the intervention group, will receive a 1-hour educational session during their routine diabetes antenatal clinic visit. In addition, they will be offered an activity tracker (following consent) to help monitor their daily step count and physical activity.
Women in both the intervention and control groups will have a fasting glucose blood sample taken the morning after delivery. Those women with normal or borderline fasting glucose levels are eligible to remain in the study, but those with type 2 diabetes will be excluded and referred to their local diabetes team.
At 6-8 weeks postnatally, both groups will complete some questionnaires, give a blood sample, have weight and blood pressure measurements recorded. Women will be offered free referral to a commercial weight management organization for 12 weeks, with a possible extension for another 12 weeks). Over the 12 months of the study, the PAIGE2 team will contact participants intermittently by text and telephone to encourage them to eat healthily and increase their physical activity. If the participants' partner is also willing to take part, the partner will be sent an activity tracker to monitor physical activity and the research team will keep in intermittent contact with the partner by text and telephone during the study.
Women allocated to the control group will be offered a free 12-week referral to a commercial weight management organization at the end of the study.
Both groups will be asked to attend 2 further study visits at 6 and 12 months after delivery. This will involve completion of some questionnaires, a blood test, weight and blood pressure measurements.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard care
Standard care
Standard care
Care routinely provided to all pregnant women diagnosed with GDM
PAIGE2 intervention
One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
PAIGE2 lifestyle intervention
Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PAIGE2 lifestyle intervention
Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
Standard care
Care routinely provided to all pregnant women diagnosed with GDM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Women with a booking BMI ≥ 25 kg/m2 at \<14 weeks gestation
3. GDM has been diagnosed in their current pregnancy.
4. Women will only continue to be included in the study if their fasting plasma glucose the morning after delivery indicates normality or impaired fasting plasma glucose outside of pregnancy (i.e.\<7 mmol/l).
5. Women with a history of GDM directly preceding the current pregnancy, and who were given lifestyle advice and were performing self-monitoring of blood glucose from early pregnancy, will also be included if capillary glucose monitoring exceeds target values (fasting ≥ 5.3 mmol/l (95 mg/dl), 1h postprandial plasma glucose ≥ 7.8 mmol/l (140 mg/dl) thus negating the need for an OGTT.
\-
Exclusion Criteria
b.) History of diabetes outside of pregnancy or FPG ≥7 mmol/l the morning after delivery.
c.) History of heart, liver or chronic renal disease. d.) Medications that adversely affect glucose tolerance (e.g. steroids). e.) Inability to participate in moderate physical activity outside of pregnancy.
f.) Moderate/severe depressive illness or excess alcohol consumption. g.) Inability to understand adequately verbal explanations or written information in English, or special communication needs.
h.) Women who are planning another pregnancy within the next 12 months following delivery.
* If a woman requests an earlier discharge that does not allow time for the FPG test, she will be offered an appointment to return to the maternity unit within four weeks of birth for retesting.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northern Health and Social Care Trust
OTHER_GOV
South Eastern Health and Social Care Trust
OTHER
Interreg
OTHER
Our Lady of Lourdes Hospital, Drogheda
OTHER_GOV
Sligo General Hospital
OTHER
Letterkenny University Hospital
UNKNOWN
Belfast Health and Social Care Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David McCance
Role: PRINCIPAL_INVESTIGATOR
Belfast Health and Social Care Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Victoria Hospital
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
McAuley E, Fleck O, Cassidy L, Kemp BJ, Cupples G, Kelly B, Creighton RM, Graham U, Wallace H, Patterson CC, McCance DR. A pragmatic lifestyle intervention for overweight and obese women with gestational diabetes mellitus (PAIGE2): A parallel arm, multicenter randomized controlled trial study protocol. Front Clin Diabetes Healthc. 2023 Mar 24;4:1118509. doi: 10.3389/fcdhc.2023.1118509. eCollection 2023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18/NI/0228
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.